Dimerix Limited (DXB) is a clinical-stage biopharmaceutical company focused on improving the lives of patients with inflammatory diseases, including kidney disease. The company is developing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for orphan respiratory / renal Disease. Both DMX-200 and DMX-700 were identified using Dimerix's proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), a scalable and globally applicable technology platform that enables the understanding of receptor interactions to rapidly screen and identify new drug opportunities.
Find out what a historical investment in Dimerix would be worth today using our DXB stock calculator.
Buying DXB shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Dimerix in minutes.
Sign up with some I.D. and zero paperwork
Add funds to your account
Make your first investment in DXB
What is the ticker symbol of Dimerix?
The ticker symbol for Dimerix is DXB.
How much is one share of DXB?
One share of DXB is valued at $0.19 as of 20 November 2026.
What is the market capitalisation of Dimerix DXB?
As of 20 November 2026 Dimerix has a market cap of $111.07M.
What is the P/E ratio of DXB?
The Price to Earnings ratio of DXB is -3.82.
What is the Earnings Per Share of DXB?
The Earnings Per Share of DXB is -$0.05.
What is the 52-week high for Dimerix stock?
The Dimerix 52-week high stock price is $0.67.
What is the 52-week low for Dimerix stock?
The Dimerix 52-week low stock price is $0.16.
Can I buy DXB shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy DXB shares and over 13,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.